Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: A systematic review of efficacy and safety in clinical trials

European Journal of Haematology

Volumn 96, Issue 4, 2016, Pages 389-396

  Zhu, Yangmin ^a   Tan, Youping ^a   Ou, Ruiming ^a   Zhong, Qi ^a   Zheng, Liling ^a   Du, Yuanyuan ^a   Zhang, Qing ^a   Huang, Jing ^a  

^a GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

B cell malignancy; CD19; Chimeric antigen receptor; Survival analysis

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; CD19 MOLECULE, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE KIDNEY FAILURE; APHASIA; APLASIA; ARTICLE; B LYMPHOCYTE APLASIA; BACTEREMIA; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CHIMERIC ANTIGEN RECEPTOR MODIFIED T LYMPHOCYTE; CONDITIONING; CONFUSION; DIARRHEA; DRUG TARGETING; DYSPNEA; FATIGUE; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERTRANSAMINASEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOGLOBULIN DEFICIENCY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; SAFETY; SINUS TACHYCARDIA; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; ADOPTIVE IMMUNOTHERAPY; ADULT; B LYMPHOCYTE; BEHAVIOR THERAPY; CELL ENGINEERING; CLINICAL TRIAL (TOPIC); CYTOLOGY; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD19; B-LYMPHOCYTES; BEHAVIOR THERAPY; CELL ENGINEERING; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84936856687     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12602     Document Type: Article

References (35)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
2. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
3. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012;14:405-15.
4. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009;32:169-80.
5. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996;157:836-43.
6. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004;172:104-13.
7. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822-6.
8. Maher J. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr Gene Ther 2014;14:35-43.
9. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35.
10. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676-84.
11. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453-64.
12. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified t cells for acute lymphoid leukemia. New Engl J Med 2013;368:1509-18.
13. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:138r-77r.
14. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507-17.
15. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245-56.
16. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122:2965-73.
17. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T Cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-8.
18. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
19. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:73r-95r.
20. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
21. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
22. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.
23. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013;122:4129-39.
24. June C, Maus M, Plesa G, Johnson L, Zhao Y, Levine B, Grupp S, Porter D. Engineered T cells for cancer therapy. Cancer Immunol Immunother 2014;63:969-75.
25. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3:388-98.
26. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014;257:127-44.
27. Turtle C. Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol 2014;99:132-40.
28. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8 + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
29. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014;65:333-47.
30. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012;14:405-15.
31. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-33.
32. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71.
33. Fujiwara H. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Int J Hematol 2014;99:123-31.
34. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.
35. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 2011;365:725-33.